

AMENDMENTS TO THE CLAIMS

Listing of Claims:

1-42. (Cancelled)

43. (Currently Amended) A method of treating inflammatory bowel disease, said method comprising administering to a subject in need thereof an anti-interleukin-6 receptor antibody which binds to human interleukin-6 receptor encoded by the cDNA contained in the plasmid pIBBSF2R deposited as FERM BP-2232, blocks binding of IL-6 to the IL-6 receptor, blocks signal transduction by IL-6, and inhibits biological activity of IL-6.
44. (Cancelled)
45. (Previously Presented) The method according to claim 43, wherein the anti-interleukin-6 receptor antibody is a chimeric antibody.
46. (Previously Presented) The antibody according to claim 43, wherein the anti-interleukin-6 receptor antibody is a humanized antibody.
47. (Previously Presented) A method according to any one of claims 43, 45 or 46, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.